ReviewBiochemical pharmacology2022
Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.
Review in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Association Between Metabolic Syndrome and Its Components and the Risk of Head and Neck Cancer: A Systematic Review and Meta-Analysis.Cancer medicine · 2025Pooled it
- Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials.Blood advances · 2025Trial
- Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review).Oncology letters · 2026Review
- Association between non-high-density lipoprotein cholesterol and high-risk intraductal papillary mucinous neoplasm.Discover oncology · 2026Article
- Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology.Biomolecules · 2026Review
- Germline APOE ε2 homozygosity and reduced risk of breast cancer: a population-based cohort study.Breast cancer research : BCR · 2026Article
- From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.Endocrine · 2026Review
- The preoperative LDL-C to HDL-C ratio evaluates prognosis in hepatocellular carcinoma patients after hepatectomy.Discover oncology · 2026Article
- Cholesterol synthases suppress metastasis and stemness through PDIA4/ACLY or SYVN1/SCD1 axis in advanced colorectal cancer.Communications biology · 2026Article
- Serum uric acid to HDL-cholesterol ratio predicts all-cause mortality in cancer patients based on NHANES data.Medicine · 2026Article
- Platelet-to-high-density lipoprotein ratio predicts postoperative overall survival in hepatocellular carcinoma: a retrospective cohort study.World journal of surgical oncology · 2026Article
- HDL Cholesterol Levels and Pancreatic Cancer Risk: Protective Effects Revealed.Current cancer drug targets · 2026Article
- Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway.Frontiers in pharmacology · 2026Article
- Dietary Soy Isoflavone Alleviates Oxidized Fish Oil-Induced Growth Inhibition and Hepatic Injury in Rice Field Eel (Animals : an open access journal from MDPI · 2025Article
- Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via interactions with HRAS to facilitate cholesterol synthesis.Oncology letters · 2025Article
- Conundrum of Cholesterol Management and Health Implications of Low Cholesterol Levels: A Narrative Review.JNMA; journal of the Nepal Medical Association · 2025Review
- Targeting cholesterol metabolism: a promising therapy strategy for cancer.Acta pharmacologica Sinica · 2025Review
- Article
- Bioactive Properties ofFoods (Basel, Switzerland) · 2025Article
- One-year longitudinal association between changes in aortic regional morphology and muscle mass in cancer.Scientific reports · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cholesterol is an amphipathic sterol molecule that is vital for maintaining normal physiological homeostasis. It is a relatively complicated molecule with 27 carbons whose synthesis starts with 2-carbon units. This in itself signifies the importance of this molecule. Cholesterol serves as a precursor for vitamin D, bile acids, and hormones, including estrogens, androgens, progestogens, and corticosteroids. Although essential, high cholesterol levels are associated with cardiovascular and kidney diseases and cancer initiation, progression, and metastasis. Although there are some contrary reports, current literature suggests a positive association between serum cholesterol levels and the risk and extent of cancer development. In this review, we first present a brief overview of cholesterol biosynthesis and its transport, then elucidate the role of cholesterol in the progression of some cancers. Suggested mechanisms for cholesterol-mediated cancer progression are plentiful and include the activation of oncogenic signaling pathways and the induction of oxidative stress, among others. The specific roles of the lipoprotein molecules, high-density lipoprotein (HDL) and low-density lipoprotein (LDL), in this pathogenesis, are also reviewed. Finally, we hone on the potential role of some cholesterol-lowering medications in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.